Shanghai Junshi Biosciences Unit Passes US FDA On-Site Inspection; Shares Slide 5%

MT Newswires Live
2025/10/23

Shanghai Junshi Biosciences (HKG:1877) said its wholly owned unit, Suzhou Union Biopharm, has passed an unannounced on-site inspection conducted by the US Food and Drug Administration, according to a Wednesday Hong Kong bourse filing.

Shares of the biopharmaceutical firm were down nearly 5% in Thursday morning trade.

The inspection, held from June 16 to June 24, reviewed compliance with current good manufacturing practice standards at Suzhou Union's Wujiang production base, which manufactures the company's toripalimab injection.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10